Currently, the antiangiogenic drugs used in clinic mainly include vascular endothelial growth factor (VEGF), its receptor VEGFR, and VEGFR tyrosine kinase inhibitors (TKIs), etc. (74) As a vascular rich tumor, the special structure of the new vessel wall of HCC often makes it difficult for anti-tumor drugs and immune cells to reach the tumor site. The gene discussed is KDR; the disease is hepatocellular carcinoma.